search
Back to results

Temocillin Pharmacokinetic in Hemodialysis

Primary Purpose

Gram-Negative Bacterial Infections, Renal Failure Chronic Requiring Hemodialysis

Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
temocillin PK/PD in haemodialysis
Sponsored by
AZ Sint-Jan AV
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gram-Negative Bacterial Infections focused on measuring temocillin, PD/PD, T>MIC

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • all patients under treatment with haemodialysis for ESRD for whom a treatment with temocillin was indicated according to the attending physician were eligible for the study.

Exclusion Criteria:

  • an age of less than 18 years
  • an estimated life-expectance of < 24 hours due to major co-morbid conditions
  • pregnancy
  • an IgE-mediated allergy to penicillins
  • patients not giving informed consent.

Sites / Locations

  • AZ Sint-Jan Brugge Oostende AV
  • Louvain Drug Research Institute (LDRI)

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

temocillin PK/PD in haemodialysis

Arm Description

Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session

Outcomes

Primary Outcome Measures

% of the dosing interval time above an MIC of 8 and 16 mg/L (% T>MIC 8 or 16 mg/L)
Is T > MIC 8 and 16 mg/ML > 40 or 60 %

Secondary Outcome Measures

Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Vd (volume of distribution)
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
T1/2 (serum half life, on and of dialysis)
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Temocillin clearance (renal and non-renal)
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Temocillin reduction rate
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
temocillin removal rate
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
temocillin protein binding

Full Information

First Posted
November 2, 2014
Last Updated
January 3, 2016
Sponsor
AZ Sint-Jan AV
Collaborators
Paul Tulkens, Louvain drug research institute, belgium, Francoise Van Bambeke, Louvain drug research institute, belgium, Ana Miranda Bastos, Louvain drug research institute, belgium
search

1. Study Identification

Unique Protocol Identification Number
NCT02285075
Brief Title
Temocillin Pharmacokinetic in Hemodialysis
Official Title
A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis?
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
AZ Sint-Jan AV
Collaborators
Paul Tulkens, Louvain drug research institute, belgium, Francoise Van Bambeke, Louvain drug research institute, belgium, Ana Miranda Bastos, Louvain drug research institute, belgium

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The current study aimed to explore the pharmacokinetics of temocillin in patients treated with haemodialysis and to demonstrated whether or not the pharmacodynamics target of a time above a MIC of 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses given after haemodialysis sessions only.
Detailed Description
Background: Temocillin is a renally cleared penicillin with long serum half-live and potent activity against most gram-negative bacteria, making it an ideal candidate for treatment given on dialysis days only of severe gram-negative infections in patients with ESRD treated with haemodialysis. Endpoints: Primary: The current study aimed to demonstrated by measurement of AUC whether or not the pharmacodynamics target of a time above a MIC of 8 and 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses given after haemodialysis sessions only. Secondary: Key pharmacokinetic and dialytic parameters were determined as previously described16. The following parameters were recorded: the volume of distribution Vd (determined as Vd = dose / (Tempeak - Temtrough) in liter); the Vd/Wt (in liter/kg body weight); the non-dialysis clearance of temocillin (Ke(non-dialysis) = [ln(Tempeak) - ln(Tempre)] / time between peak level and start of next dialysis); the non-dialysis half-life (T1/2(non-dialysis) = 0.693 / Ke(non-dialysis) in hours); the dialysis clearance of temocillin (Ke(dialysis) = [ln(Tempre) - ln(Tempost)] / dialysis duration); the dialysis half-life (T1/2(dialysis) = 0.693 / Ke(dialysis) in hours); the Urea Reduction Ratio (URR = (BUNpre - BUNpost) / BUNpre); the Temocillin Reduction Ratio TRR = (Tempre - Tempost) / Tempre); the Temocillin Removal Ratio (the total amount of temocillin recovered in the dialysate, based on the area under the curve of the temocillin removal rate and the treatment time); and the AUC of temocillin. For all PK/PD analysis, the non-compartmental method using RStudio 0.98.501 with R 3.0.2 software was used. Methods: Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with intermittent haemodialysis and temocillin. Blood samples were drawn just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval. Patients were followed for 1 to 6 subsequent AUC. Dialysate samples were taken 1, 2, 3 and 4 h after the start of dialysis. All samples were taken from an arterial or venous catheter, after thorough rinsing. Serum (obtained by centrifugation after blood clotting) and dialysate was frozen (-80 C) immediately after sampling until analysis. Temocillin total and free concentrations were determined with high performance liquid chromotography(HPLC) with a LiChrospher 100 RP-18 5 μm column (Merck AG), using an elution buffer 100 mM Na acetate buffer pH 7/acetonitrile (95:5, v/v), a flow rate 1 mL/min and a Waters 2690 Alliance System (Waters Corp., Milford, MA, USA), with quantification at 235 nm as previously described.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gram-Negative Bacterial Infections, Renal Failure Chronic Requiring Hemodialysis
Keywords
temocillin, PD/PD, T>MIC

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
temocillin PK/PD in haemodialysis
Arm Type
Other
Arm Description
Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
Intervention Type
Drug
Intervention Name(s)
temocillin PK/PD in haemodialysis
Intervention Description
Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).
Primary Outcome Measure Information:
Title
% of the dosing interval time above an MIC of 8 and 16 mg/L (% T>MIC 8 or 16 mg/L)
Description
Is T > MIC 8 and 16 mg/ML > 40 or 60 %
Time Frame
two to ten days
Secondary Outcome Measure Information:
Title
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Description
Vd (volume of distribution)
Time Frame
two to ten days
Title
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Description
T1/2 (serum half life, on and of dialysis)
Time Frame
two to ten days
Title
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Description
Temocillin clearance (renal and non-renal)
Time Frame
two to ten days
Title
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Description
Temocillin reduction rate
Time Frame
two to ten days
Title
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Description
temocillin removal rate
Time Frame
two to ten days
Title
Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis
Description
temocillin protein binding
Time Frame
two to ten days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: all patients under treatment with haemodialysis for ESRD for whom a treatment with temocillin was indicated according to the attending physician were eligible for the study. Exclusion Criteria: an age of less than 18 years an estimated life-expectance of < 24 hours due to major co-morbid conditions pregnancy an IgE-mediated allergy to penicillins patients not giving informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefaan J Vandecasteele, MD, PhD
Organizational Affiliation
AZ Sint-Jan AV
Official's Role
Principal Investigator
Facility Information:
Facility Name
AZ Sint-Jan Brugge Oostende AV
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Louvain Drug Research Institute (LDRI)
City
Brussels
ZIP/Postal Code
1020
Country
Belgium

12. IPD Sharing Statement

Citations:
PubMed Identifier
24389461
Citation
Miranda Bastos AC, Vandecasteele SJ, Tulkens PM, Spinewine A, Van Bambeke F. Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. J Pharm Biomed Anal. 2014 Mar;90:192-7. doi: 10.1016/j.jpba.2013.12.002. Epub 2013 Dec 12.
Results Reference
result
PubMed Identifier
29579214
Citation
Miranda Bastos AC, Vandecasteele SJ, Spinewine A, Tulkens PM, Van Bambeke F. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. J Antimicrob Chemother. 2018 Jun 1;73(6):1630-1638. doi: 10.1093/jac/dky078.
Results Reference
derived

Learn more about this trial

Temocillin Pharmacokinetic in Hemodialysis

We'll reach out to this number within 24 hrs